GlassScriptPhysician profile
Daniel A Barocas
NPI 1225259831
$17,635.80
in general payments reported to CMS, 2019-2025
12 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $2,475 · 2021: $3,521 · 2022: $2,444 · 2023: $7,676 · 2024: $727 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,090 · Food and Beverage: $1,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,090.00 |
| Food and Beverage | $1,726.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Progenics Pharmaceuticals, INC. | $10,275.00 | 2020-2023 | Pylarify |
| Pfizer INC. | $2,091.83 | 2023 | |
| Astellas Pharma US INC | $1,932.00 | 2022 | |
| Photocure INC | $1,129.06 | 2019-2025 | Cysview |
| Ambu INC. | $800.00 | 2021 | |
| Janssen Biotech, INC. | $404.87 | 2024-2025 | Erleada, Akeega |
| Urogen Pharma, INC. | $305.35 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $263.05 | 2023-2025 | |
| Karl Storz Endoscopy-America | $210.34 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $146.26 | 2024 | Erleada |
| Intuitive Surgical, INC. | $40.55 | 2019 | |
| Ferring Pharmaceuticals INC. | $37.49 | 2024 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Barocas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.